Subscribe
shutterstock_1755486332_anton_medvedev
Anton_Medvedev / Shutterstock.com
10 August 2021EuropeSophie Topham

UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver

In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.
Generics
UK experimental use exemptions: Part 3—the expanded exemption
5 August 2021   In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Generics
UK experimental use exemptions: Part 3—the expanded exemption
5 August 2021   In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.
Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.

More on this story

Generics
UK experimental use exemptions: Part 3—the expanded exemption
5 August 2021   In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.
Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.

More features

Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Cooley adds ex-Gowling partner
Apple wins just $250 in Masimo smartwatch clash
Baker McKenzie welcomes back AI and tech transactions expert
HR, lobbying and business strategy…all in a day’s work for today’s counsel
How post-filing data rescued Novo Nordisk’s Ozempic patent in China
Jones Day hires pharma and high-tech patent litigator to London office